How Hemay005 is processed in people with liver damage
Treatments studied
Part of Skin clinical trials.
This study looks at how a new drug called Hemay005 behaves in people with mild or moderate long-term liver damage. It helps doctors understand if the drug needs a different dose for people with liver problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have stable, mild or moderate liver damage (Child-Pugh class A or B) caused by conditions like nonalcoholic fatty liver disease or alcoholic liver disease.
- You weigh at least 50 kg (men) or 45 kg (women), with a BMI between 19 and 32.
- Your other medications for liver problems have been the same for at least 28 days (or 14 days if your liver damage is moderate).
- You do not have advanced liver complications like recent bleeding, severe fluid buildup, or liver cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how a new drug, HSK39297, works in people with mild to moderate liver impairment (Child-Pugh A or B). It compares them to healthy volunteers to see how the liver affects the drug's safety and how the body processes it.
This study looks at how the medicine PF-07328948 is processed by people with different levels of liver function. It includes both healthy people and those with stable liver disease (classified as mild, moderate, or severe). The goal is to see if the liver condition affects how the drug works in the body.
This study tests how the body processes and tolerates a new experimental drug (MDR-001) in people with mild to moderate liver disease. The research helps doctors understand if the drug is safe and how it works when liver function is reduced.
This study tests whether a new drug called Hemay005 can help people with moderate to severe ulcerative colitis (a chronic bowel condition causing inflammation and symptoms like diarrhea and abdominal pain) who haven't responded well to or can't tolerate standard treatments. The goal is to reduce inflammation and improve symptoms.
This study tests how a new investigational drug called AHB-137 moves through your body and affects safety in people with mild-to-moderate liver problems compared to people with normal liver function. The goal is to understand if the drug works safely in people whose livers don't work as well as they should.
This trial tests how a drug (BMS-986435) behaves in people with normal liver function versus those with liver problems. It also checks that the drug is safe for the heart.
Hear when a new Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.